We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-0.73%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$841M
AUM Growth
-$257M
Cap. Flow
-$256M
Cap. Flow %
-30.4%
Top 10 Hldgs %
71.13%
Holding
232
New
70
Increased
34
Reduced
47
Closed
75

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$56.8M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$12.1M
3
COGT icon
Cogent Biosciences
COGT
+$9.38M
4
INCY icon
Incyte
INCY
+$7.38M
5
NKTR icon
Nektar Therapeutics
NKTR
+$3.34M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$58.4M
2
ESPR
Esperion Therapeutics
ESPR
+$9.06M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$6.4M
4
MNKD icon
MannKind Corp
MNKD
+$3.35M
5
ABBV icon
AbbVie
ABBV
+$3.03M

Sector Composition

Rank Sector Weight
1 Healthcare 15.86%
2 Consumer Staples 0.43%
3 Consumer Discretionary 0.12%
4 Materials 0.09%
5 Technology 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
51
Alnylam Pharmaceuticals
ALNY
$38.5B
$1.37M 0.16%
11,500
-7,750
-40% -$999K
ESPR
52
DELISTED
Esperion Therapeutics
ESPR
$1.36M 0.16%
18,823
-123,362
-87% -$9.06M
PRTA icon
53
PUT
Prothena Corp
PRTA
$448M
$1.34M 0.16%
431
– –
CARM
54
DELISTED
Carisma Therapeutics
CARM
$1.29M 0.15%
+61,306
New +$1.18M
INSM icon
55
PUT
Insmed
INSM
$22.6B
$1.22M 0.15%
+543
New +$14.3K
TPST icon
56
Tempest Therapeutics
TPST
$13.9M
$1.19M 0.14%
500
+295
+144% +$884K
ZSAN
57
DELISTED
Zosano Pharma Corporation
ZSAN
$1.18M 0.14%
+6,679
New +$2.23M
ARAV
58
DELISTED
Aravive, Inc. Common Stock
ARAV
$1.16M 0.14%
117,061
-48,456
-29% -$545K
ADVM
59
DELISTED
Adverum Biotechnologies
ADVM
$1.15M 0.14%
19,896
-10,104
-34% -$629K
ALXN
60
PUT
DELISTED
Alexion Pharmaceuticals
ALXN
$1.07M 0.13%
96
– –
SLS icon
61
SELLAS Life Sciences
SLS
$1.98B
$1.07M 0.13%
6,184
+4,435
+254% +$1.27M
NURO
62
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
$1M 0.12%
8,880
+6,630
+295% +$831K
ADOM
63
DELISTED
ADOMANI Inc
ADOM
$995K 0.12%
+843,407
New +$1.51M
FOLD
64
DELISTED
Amicus Therapeutics
FOLD
$976K 0.12%
+64,910
New +$988K
AKBA icon
65
Akebia Therapeutics
AKBA
$341M
$975K 0.12%
+102,338
New +$1.43M
AKAO
66
CALL
DELISTED
Achaogen Inc
AKAO
$923K 0.11%
+713
New +$8.09K
ALKS icon
67
PUT
Alkermes
ALKS
$8.47B
$910K 0.11%
157
-77
-33% -$4.5K
HYPD
68
Hyperion DeFi Inc
HYPD
$36.7M
$908K 0.11%
+1,222
New +$887K
ARMP icon
69
Armata Pharmaceuticals
ARMP
$174M
$907K 0.11%
+59,426
New +$1.05M
SGYPW
70
CALL
DELISTED
Synergy Pharmaceuticals, Inc. - Warrants
SGYPW
$907K 0.11%
4,954
+711
+17% +$130K
PRTA icon
71
Prothena Corp
PRTA
$448M
$899K 0.11%
24,500
-230
-0.9% -$8.37K
OPGN
72
DELISTED
OpGen, Inc
OPGN
$875K 0.1%
130
+119
+1,082% +$1.45M
VRTX icon
73
CALL
Vertex Pharmaceuticals
VRTX
$124B
$861K 0.1%
1,315
+396
+43% +$64.7K
MBOT icon
74
Microbot Medical
MBOT
$113M
$843K 0.1%
83,293
-40
-0% -$540
CBIO
75
Crescent Biopharma
CBIO
$608M
$838K 0.1%
+516
New +$1.07M
1 2
3
4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2018 Portfolio in Review

As of Q1 2018, Sabby Management held 232 positions worth $841M, down 23% from $1.1B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Sabby Management withdrew a net $256M in Q1 2018, closing 75 positions and reducing 47 holdings. Its most notable exit was Spark Therapeutics, Inc. Common Stock, an estimated $6.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 12% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

Against the trend, Sabby Management opened a new position in Biogen worth $50.1M.

  • Sabby Management's largest Q1 2018 buy was Biogen: 182,898 shares worth $50.1M.
  • Sabby Management added most to Nektar Therapeutics in Q1 2018, an estimated $3.34M increase.
  • Sabby Management's biggest Q1 2018 reduction was Bristol-Myers Squibb, cutting an estimated $58.4M.
  • Sabby Management fully exited Spark Therapeutics, Inc. Common Stock in Q1 2018, selling an estimated $6.4M.
  • Sabby Management's ten largest holdings make up 71% of its $841M portfolio in Q1 2018.
  • Sabby Management opened 70 new positions and closed 75 in Q1 2018.
  • Sabby Management's portfolio value fell 23% quarter-over-quarter to $841M.

Based on Sabby Management's 13F filing for Q1 2018, filed 15 May 2018.